Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Trial of Modifications to Radical Prostatectomy

Phase 3

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Procedure: Transverse versus vertical closure
Procedure: Lymph node template
Drug: antibiotic prophylaxis
Drug: Hemostatic Agent

First Posted Date: 2011-08-02

Last Posted Date: 2024-08-14

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 3204

Registration Number: NCT01407263

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center @ Nassau (Consent only), Uniondale, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 2 locations

Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy

Phase 2

Completed

Conditions: Acute Promyelocytic Leukemia

Interventions: Drug: Tretinoin and Arsenic Trioxide

First Posted Date: 2011-07-28

Last Posted Date: 2021-11-30

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 17

Registration Number: NCT01404949

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
New York Presbyterian Hospital-Weill Medical College of Cornell University, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States

and more 9 locations

Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)

Phase 2

Completed

Conditions: Renal Cell Carcinoma

Interventions: Drug: everolimus and bevacizumab

First Posted Date: 2011-07-22

Last Posted Date: 2022-02-01

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 57

Registration Number: NCT01399918

Locations: 🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States

and more 4 locations

Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC)

Completed

Conditions: Esophageal Cancer
Adenocarcinoma

Interventions: Other: serum and tissue mesothelin

First Posted Date: 2011-07-13

Last Posted Date: 2024-10-28

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 371

Registration Number: NCT01393483

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies

Phase 1

Completed

Conditions: Metastatic Solid Tumor
Lymphoma
Myeloproliferative Neoplasms (MPN)

Interventions: Drug: PU-H71

First Posted Date: 2011-07-13

Last Posted Date: 2023-03-28

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 47

Registration Number: NCT01393509

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma

Phase 1

Completed

Conditions: Glioblastoma
Brain Cancer
Malignant Glioma NOS
MALIGNANT GLIOMA
Anaplastic Astrocytoma (AA)
Anaplastic Oligodendroglioma (AO)
Anaplastic Oligo-astrocytoma (AOA)
Anaplastic Mixed Gliomas

Interventions: Other: Bevacizumab & Stereotactic Radiotherapy

First Posted Date: 2011-07-12

Last Posted Date: 2019-11-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 15

Registration Number: NCT01392209

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States

and more 2 locations

Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others

Completed

Conditions: Thyroid Cancer
Papillary Microcarcinoma

Interventions: Behavioral: Focus groups

First Posted Date: 2011-07-12

Last Posted Date: 2017-06-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 21

Registration Number: NCT01392222

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Understanding Decision Making Processes for Undergoing Genetic Testing Among Women With Newly Diagnosed Breast Cancer

Completed

Conditions: Breast Cancer

Interventions: Genetic: BRCA testing and questionnaire assessments

First Posted Date: 2011-07-01

Last Posted Date: 2017-11-08

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 108

Registration Number: NCT01386411

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis

Not Applicable

Completed

Conditions: Amyloidosis
Light Chain Deposition Disease (LCDD or MIDD)
Monoclonal Immunoglobulin Deposition Disease (MIDD)
Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD)

Interventions: Drug: Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone

First Posted Date: 2011-06-28

Last Posted Date: 2020-04-07

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 20

Registration Number: NCT01383759

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States

and more 2 locations

Dose-Escalation Safety and Pharmacokinetic Study of Iso-Fludelone in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: Iso-Fludelone

First Posted Date: 2011-06-23

Last Posted Date: 2023-02-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 29

Registration Number: NCT01379287

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy